Ken Griffin Mesoblast LTD Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.39 $68,800 - $95,632	-68,800 Reduced 15.88%	364,500 $400,000
Q3 2023 Nov 14, 2023	BUY	$1.22 - $4.83 $70,394 - $278,691	57,700 Added 15.36%	433,300 $532,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $4.44 $89,385 - $134,532	-30,300 Reduced 7.46%	375,600 $1.47 Million
Q1 2023 May 15, 2023	SELL	$2.94 - $4.18 $147,588 - $209,836	-50,200 Reduced 11.01%	405,900 $1.34 Million
Q4 2022 Feb 14, 2023	BUY	$2.73 - $3.7 $149,058 - $202,020	54,600 Added 13.6%	456,100 $1.33 Million
Q3 2022 Nov 14, 2022	BUY	$0.48 - $3.48 $45,264 - $328,164	94,300 Added 30.7%	401,500 $1.02 Million

151K

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $1.2B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.